Effects of lactobacillus on normal and tumour bearing mice

EFFECTS OF LACTOBACILLUS ON NORMAL AND TUMOUR BEARING MICE SEOW SHIH WEE B.Sc (HON.) NUS A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY DEPARTMENT OF SURGERY NATIONAL UNIVERSITY OF SINGAPORE Acknowledgements I would like to extend my heartfelt gratitude to my supervisors, Dr Ratha Mahendran, Prof Bay Boon Huat and A/P Lee Yuan Kun for their direction and invaluable advice throughout my candidature and during the process of producing this dissertation. Survival throughout the entire duration of the candidature could not have been possible without the help of all members of the lab, both past and present, some of whom became firm friends of mine. Special thanks to Juwita, Rachel, Shirong and Mathu for the laughter and support which never failed to come when most needed. Many thanks also to Mrs Ng Geok Lan, Poon Zhung Wei and Ms Pan Feng from the Immunohistochemistry laboratory (Anatomy), Ms Chan Yee Gek (Electron Microscopy Unit), and Mr Low Chin Seng (Microbiology) for their assistance and for imparting their lab skills to me. Finally, this dissertation is dedicated in its entity to my husband and parents from whom I draw strength for sustenance and determination. THANKS! i Acknowledgments i Table of contents ii List of Abbreviations viii List of Figures xi List of Tables xiii List of publications and conference papers xiv Summary xvi Introduction 1.1. Bladder cancer – an overview 1.2. Bladder cancer therapy 1.2.1. Surgery 1.2.2. Intravesical chemotherapeutic agents 1.2.3. Bacillus Calmette-Guérin (BCG) Immunotherapy of Bladder Cancer 1.2.4. ImmuCyst® [Bacillus Calmette-Guérin (BCG), substrain Connaught] 1.3. Mechanisms of BCG action 1.3.1. Fibronectin-mediated 1.3.2. Recruitment of immune cells 1.3.3. Pro-inflammatory cytokines 1.3.4. BCG viability influences treatment efficacy 1.4. Side-effects associated with BCG immunotherapy 11 1.4.1. Attempts to alleviate BCG side-effects 11 1.5. Probiotics and Lactobacillus species 12 1.5.1. Beneficial health properties of Lactobacillus species 13 1.5.1.1. Women’s reproductive and bladder health 13 1.5.1.2. Alleviating allergies 13 1.5.1.3. Boosts overall immunity 14 1.5.1.4. Ensuring good gastrointestinal health and prevention of 15 gastrointestinal infections 1.6. The genus Lactobacillus and cancer 16 1.6.1. Postulated anti-cancer mechanisms of Lactobacillus species 17 1.6.1.1. Alteration to gut microflora 17 ii 1.6.1.2. Alteration to metabolic activities of gut microflora 17 1.6.1.3. Adsorbing and facilitating excretion of carcinogens 17 1.6.2. Lactobacillus species and bladder cancer 20 1.7. Unanswered questions and inconsistencies in current reports 21 1.8. Lactobacillus rhamnosus strain GG (LGG) 22 1.9. Animal models of bladder cancer 22 1.10. Types of cell death in cancer treatment 28 1.10.1. Apoptosis 28 1.10.1.1. Nonsteroidal anti-inflammatory drugs (NSAID) activated gene 29 1.10.2. Necrosis 29 1.10.3 Autophagy 30 1.11. Scope of study 32 2. Materials and Methods 33 2.1. Bacteria culture 34 2.1.1. Lactobacillus rhamnosus strain GG (LGG) 34 2.1.2. Heat-killed LGG 34 2.1.3. Lyophilised LGG (lyo LGG) 34 2.1.4. LGG-green fluorescent protein (LGG-GFP) 35 2.1.5. Live Bacillus Calmette Guerin (BCG) 35 2.2. Tumour cell lines 36 2.3. Animals 36 2.3.1. Orthotopic procedures 36 2.3.2. Assessing the safe use of LGG in mice 37 2.3.2.1. LGG localisation and translocation 37 2.3.2.2. Immune cell population changes after bacteria instillations in healthy 37 mice 2.3.2.3. Expression of inflammatory cytokines and receptors after LGG 40 instillation in healthy mice 2.3.2.4. Reverse transcriptase polymerase chain reaction (RT-PCR) 44 2.3.2.5. Optimising LGG instillation schedule 48 2.3.3. Orthotopic tumour model 49 iii 2.3.3.1. Tumour implantation 49 2.3.3.2. Free Prostate Specific Antigen (f-PSA) Chemiluminescence 49 Immunoassay Kit 2.3.3.3 Monitoring tumour implantation efficiency and disease progression 50 2.3.4. Treatment of bladder cancer 51 2.3.4.1. Intravesical therapy with bacteria 51 2.3.5. Metastasis confirmation 52 2.3.6. Analysis of TNFα, TGFβ and IL10 expression in local lymph nodes 53 2.3.7. Urinary cytokines 54 2.3.8. Bladder protein isolation 55 2.3.8.1. Analysis of cytokines in bladder post-microbe instillations 55 2.3.8.2. Confirmation of cytokine protein array data with ELISA 56 2.3.9. Immunohistochemistry 57 2.4. Re-selection of tumour cell line 59 2.5. Co-culture of LGG with mammalian cells 59 2.5.1. In vitro stimulation of splenocytes with live or lyo LGG 60 2.5.2. Effects of LGG on MB49 cell proliferation 60 2.5.3. Cell cycle analysis 60 2.5.4. 62 2.5.5. Nonsteroidal anti-inflammatory drugs (NSAID) activated gene (NAG-1) real-time PCR Caspase-3 activity assay 62 2.5.6. Electron microscopy 64 2.6. Statistical analysis 65 3. Results 66 3.1. Assessing the persistence and immunomodulatory effects of LGG 67 3.1.1. Live LGG up regulates TNFα expression in splenocytes 67 3.1.2. Persistence of LGG in the bladder and other tissues after one and six 68 instillations 3.1.3. Comparing the ability of LGG and BCG to stimulate cytokine and 70 chemokine gene expression in the bladder 3.1.3.1. General observations 70 iv 3.1.3.2. Analysis of mouse inflammatory cytokines and receptors with 71 microarray 3.1.3.3. Analysis of mouse inflammatory cytokines, chemokines and 74 receptors with RT-PCR 3.1.3.4. Immune cell recruitment to the local lymph nodes and bladder 78 3.2. Modulating LGG’s immunogenicity through lyophilisation 80 3.2.1. Lyophilised LGG remains viable after lyophilisation 80 3.2.2. Live and lyo LGG stimulates cytokine mRNA and protein 80 expressions 3.2.3. Lyo LGG instillations did not result in host morbidity or mortality 84 3.2.4. Effect of one or two Lyo GG instillations a week on gene expression 84 in the bladder 3.2.5. Lyo LGG instillations attract activated and mature dendritic cells to 87 the bladder 3.2.6. Lyo LGG instillations changed the immune cell populations of the 88 local lymph nodes 3.3. Assessing and evaluating the anti-tumour efficacy of LGG in vivo 90 3.3.1. Monitoring orthotopic tumour implantation and disease progression 91 3.3.2. General observations 92 3.3.3. LGG instillations conferred survival advantage 92 3.3.4. LGG therapy conferred protective effect over PBS 93 3.3.5. Elucidating LGG’s anti-tumour mechanisms 93 3.3.5.1. Analysis of bladder proteins post-LGG therapy 93 3.3.5.2. Bladder protein ELISA 98 3.3.5.3. Profiling systemic and local immune response post-LGG therapy 101 3.3.5.4. Immune cell population in the local lymph nodes after LGG therapy 102 3.3.6. Histopathological and immunohistochemical analysis of Control PBS 103 and lyo LGG-instilled bladders 3.3.6.1. Histopathology and immunohistochemistry 104 3.3.6.2. Lyo LGG mobilised large numbers of neutrohpils and macrophages 105 into the tumour v 3.4. Comparing the efficacy of lyophilised LGG as an 109 immunotherapeutic with BCG 3.4.1. Re-selection of tumour cell line 109 3.4.2. A comparison of treatment efficacy between BCG Immucyst and lyo 111 LGG 3.4.2.1. General observations of Immucyst-treated mice 111 3.4.2.2. Lyo LGG is as efficacious as Immucyst in treating bladder cancer 111 3.4.2.3. Lyo LGG and Immucyst and tumour metastasis 113 3.4.3. Lyo LGG and BCG instillations did not alter urine TNFα and IL10 114 levels 3.4.4. Lyo LGG increased TNFα mRNA expression in local lymph nodes 116 3.5. Analysis of direct cytotoxic effects of LGG 119 3.5.1. Live LGG but not heat-killed LGG induces cytotoxicity 119 3.5.2. Live LGG inhibits murine and human bladder cancer cell 120 proliferation LGG induces sub-G1 population in the absence of direct contact with 3.5.3. 121 cancer cells 3.5.4. Lyo LGG is as efficacious as live LGG in inducing a large sub-G1 122 population 3.5.5. LGG increases NAG-1 mRNA expression in MGH cells 122 3.5.6. LGG did not induce caspase-3 activity 125 3.5.7. Live and lyo LGG induces cell death in MGH cells 125 4. Discussion 129 4.1. LGG as a non-pathogenic intravesical immunotherapeutic 131 4.2. Lyophilised LGG - a better immunostimulant than whole live 136 LGG 4.3. cRNA array versus semi-quantitative polymerase chain reaction 140 4.4. Treating bladder cancer with Lactabacillus rhamnosus strain GG 141 LGG’s indirect killing mechanisms 142 4.5.1. Role of proteins 142 4.5.2. Role of immune cells 145 4.5. ` vi 4.6. Effects of LGG in a healthy versus diseased bladder 149 4.7. LGG’s direct killing mechanisms 150 4.8. Lactic acid is not the cytotoxic metabolite 152 4.9. Translating in vitro evidence to in vivo tumour models 153 4.10. Conclusion 154 4.11. Future directions 155 References 158 vii List of Abbreviations (in alphabetical order) APC Allophycocyanin BCG Bacillus Calmette-Guerin BSA Bovine serum albumin Beta-defensin β-Def-1 CARE Centre for Animal Resources Ccl Chemokine (C-C motif) ligand CD Cluster of Differentiation protein CD3-FTIC Monoclonal Antibody to CD3, Fluorescein isothiocyanate (FITC) conjugated CD4-PE Monoclonal Antibody to CD4, Phycoerythrin (PE) conjugated cDNA Complementary deoxyribonucleic acid CFU Colony Forming Units CIS Bladder carcinoma in situ Cxcl Chemokine (C-X-C motif) ligand DAB 3,3'-diaminobenzidine DEPC Diethyl pyrocarbonate DR Death Receptor ELISA Enzyme-linked immunosorbent assay FANFT N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide FBS Fetal bovine serum Fc epsilon receptor Fcεr1g Fc gamma receptor Fcγr1 Foxp3 Forkhead box P3 GA Glutaraldehyde GAG glycoaminoglycan GAPDH Glyceraldehyde 3-Phosphate Dehydrogenase GMCSF Granulocyte-Macrophage Colony-Stimulating Factor H&E Hematoxylin & Eosin Staining IACUC Institutional Animal Care and Use Committee ICAM-1 Intracellular adhesion molecule Interferon gamma IFNγ Ig Immunoglobulin IHC Immunohistochemistry ILInterleukinIL3Rb Interleukin receptor beta LPS Lipopolysaccharide iNOS Inductible nitric oxide synthase IP-10 Interferon-inducible protein 10 LAB Lactic acid bacteria LAKs Lymphokine-Activated Killer cells LcS Lactobacillus casei strain Shirota LGG Lactobacillus rhamnosus strain GG LGG-GFP LGG-green fluorescent protein LIX Chemokine (C-X-C motif) Ligand Lyo LGG Lyophilised LGG viii List of Abbreviations (continued) MAKs Macrophage-Activated Killer cells MBT-2 Mouse bladder tumour MHC Major Histocompatibility Complex MIP2 Macrophage inflammatory protein MRS de Man, Rogosa, Sharpe MMC Mitomycin C NAG-1 Nonsteroidal anti-inflammatory drugs (NSAID) activated gene NK Natural Killer cells NUS National University of Singapore OPN Osteopontin O+I Oral & intravesical therapy group PARP Poly (ADP-ribose) Polymerase PBS Phosphate buffered saline PF4 Platelet factor PG RPMI complete media with Penicillin G (5000units/ml) PLL Poly-L-lysine PMN Polymorphonuclear cells Pro-MMP9 Matrix metalloproteinase 9, pro-form PS RPMI complete media with Penicillin G (5000units/ml) and Streptomycin (5mg/ml) PSA Prostate specific antigen PtdSer Phosphotidylserine RANTES Regulated upon Activation, Normal T-cell Expressed, and Secreted, also known as Ccl5 RBC Red blood cell RNA Ribonucleic acids RT Room temperature RT-PCR Reverse transcriptase polymerase chain reaction RAC1 Ras-related C3 botulinum toxin substrate SCID Severe Combined Immunodeficiency Scye1 Small inducible cytokine subfamily E, member SD Standard deviation sTNF RI Soluble tumour necrosis factor receptor inhibitor I TCC Transitional Cell Carcinoma Tumour Growth Factor, beta TGF-β Th1 Helper T cell responses Thiotepa N,N'N'-triethylenethiophosphoramide Thymus Ck1 Thymus chemokine TIFF Tagged Image File Format TLR Toll-like receptor Tumour Necrosis Factor, alpha TNFα TUR Transurethral resection TMB 3, 3’, 5, 5’-tetramethylbenzidine TBS Tris-buffered saline ix 99 Oliveira1 PA, Colaço1 A, De la Cruz P LF, Lopes C. Experimental bladder carcinogenesis-rodent models. Exp Oncol. 28: - 11. 2006. 100 Mickey DD, Mickey GH, Murphy WM, Niell HB, Soloway MS. In vitro characterisation of four N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) induced mouse bladder tumours. J Urol. 127: 1233 - 37. 1982. 101 Xiao Z, McCallum TJ, Brown KM, Miller GG, Halls SB, Parney I, Moore R. Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Br J Cancer. 81: 638 - 46. 1999. 102 Russell PJ, Raghavan D, Gregory P, Philips J, Wills EJ, Jelbart M, Wass J, Zbroja RA, Vincent PC. Bladder cancer xenografts: a model of tumour cell heterogeneity. Cancer Res. 46: 2035 - 40, 1986. 103 Polvsen CO. Status of chemotherapy, radiotherapy, endocrine therapy and immunotherapy studies of human cancer in the nude mouse. In: J. Fogh and B. C. Giovanella (eds.), The Nude Mouse in Experimental and Clinical Research. Pg 437- 56. New York: Academic Press, Inc. 1978. 104 Kyriazis AP, DiPersio L, Michael GJ, Peace AJ, Sinnett JD. Growth patterns and metastatic behavior of human tumours growing in athymic mice. Cancer Res. 38: 3186 - 90. 1978. 105 Soloway MS, Masters S. Urothelial susceptibility to tumour cell implantation: influence of catheterisation. Cancer. 46: 1158 - 63. 1980. 175 106 Ibrahiem EH, Nigam VN, Brailovsky CA, Madarnas P, Elhilali M. Orthotopic implantation of primary N-[4-(5-Nitro-2-furyl)-2-thiazolyl] formamide-induced bladder cancer in bladder submucosa: an animal model for bladder cancer study. Cancer Res. 43: 617 - 22. 1983. 107 Coplen DE, Marcus MD, Myers JA, Ratliff TL, Catalona WJ. Long-term followup of patients treated with or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free tumor. J Urol 144: 652 – 57. 1990. 108 Wu Q, Esuvaranathan K, Mahendran R. Monitoring the response of orthotopic bladder tumours to granulocyte macrophage colony-stimulating factor therapy using the prostate-specific antigen gene as a reporter. Clin Cancer Res. 10: 6977 - 84. 2004. 109 Gunther JH, Jurczok A, Wulf T, Brandau S, Deinert I, Jocham D, Bohle A. Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res. 59: 2834 - 37. 1999. 110 Soloway MS, Nissenkorn I, McCallum L. Urothelial susceptibility to tumour cell implantation: comparison of cauterization with N-methyl-N-nitrosourea. Urology. 21: 159 - 61. 1983. 111 Soloway M. Intravesical and systemic chemotherapy of murine bladder cancer. Can Res. 43: 2918 - 29. 1977. 176 112 Chade DC, Andrade PM, Borra RC, Leite KR, Andrade E, Villanova FE, Srougi M. Histopathological characterization of a syngeneic orthotopic murine bladder cancer model. Int Braz J Urol. 34(2): 220 - 26; discussion 226 - 29. 2008. 113 Loskog A, Ninalga1 C, Hedlund T, Alimohammadi M, Malmstrom P-U, Totterman TH. Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy. Lab Anim. 39(4): 384 - 93. 2005. 114 Soloway M. Single and combination chemotherapy for primary murine bladder cancer. Cancer. 36: 333 - 40. 1975. 115 Shibayama T, Tachibana M, Deguchi N, Jitsukawa S, Tazaki H. SCID mice: a suitable model for experimental studies of urologic malignancies. J Urol. 146: 1136 -37. 1991. 116 Jiang F, Zhou XM. A model of orthotopic murine bladder (MBT-2) tumour implants. Urol Res. 25: 179 - 82. 1997. 117 Summerhayes I, Franks LM. Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J Natl Cancer Inst. 62: 1017- 23. 1979. 118 Bisson JF, Parache RM, Droulle P, Notter D, Vigneron C, Guillemin F. A new method of implanting orthotopic rat bladder tumour for experimental therapies. Int J Cancer. 102: 280 - 85. 2002. 177 119 Kroemer G, El-Deiry WS, Golstein P, Peter ME, Vaux D, Vandenabeele P, Zhivotovsky B, Blagosklonny MV, Malorni W, Knight RA, Piacentini M, Nagata S, Melino G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ. 12 Suppl 2: 1463 67. 2005. 120 Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol. 2: 965 - 75. 2002. 121 Henson PM, Hume DA. Apoptotic cell removal in development and tissue homeostasis. Trends Immunol. 27: 244 - 50. 2006. 122 Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. Cyclooxygenase inhibitors regulate the expression of a TGF-b superfamily member that has proapoptotic and antitumourgenic activities. Mol. Pharmacol. 59: 901 - 08. 2001. 123 Kim KS, Baek SJ, Flake GP, Loftin CD, Calvo BF, Eling TE. Expression and regulation of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) in human and mouse tissue. Gastroenterology. 122: 1388 - 98. 2002. 124 Lee SH, Yamaguchi K, Kim JS, Eling TE, Safe S, Park Y, Baek SJ. Conjugated linoleic acid stimulates an anti-tumourigenic protein NAG-1 in an isomer specific manner. Carcinogenesis. 27: 972 - 81. 2006. 178 125 Baek SJ, Kim JS, Jackson FR, Eling TE, McEntee MF, Lee SH. Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells. Carcinogenesis. 25: 2425 - 32. 2004. 126 Jang TJ, Kim NI, Lee CH. Proapoptotic activity of NAG-1 is cell type specific and not related to COX-2 expression. Apoptosis. 11: 1131 - 38. 2006. 127 Jang TJ, Kang HJ, Kim JR, Yang CH. Non-steroidal anti-inflammatory drug activated gene (NAG-1) expression is closely related to death receptor-4 and -5 induction, which may explain sulindac sulfide induced gastric cancer cell apoptosis. Carcinogenesis. 25: 1853 - 58. 2004. 128 Ko JK, Leung WC, Ho WK, Chiu P. Herbal diterpenoids induce growth arrest and apoptosis in colon cancer cells with increased expression of the nonsteroidal anti-inflammatory drug-activated gene. Eur J Pharmacol. 559: - 13. 2007. 129 Lim JH, Park JW, Min DS, Chang JS, Lee YH, Park YB, Choi KS, Kwon TK. NAG-1 up-regulation mediated by EGR-1 and p53 is critical for quercetininduced apoptosis in HCT116 colon carcinoma cells. Apoptosis. 12: 411 - 21. 2007. 130 Raff M. Cell suicide for beginners. Nature. 396: 119 - 22. 1998. 131 Amaravadi RK, Thompson CB. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res. 13: 7271 - 79. 2007. 179 132 Russo F, Orlando A, Linsalata M, Cavallini A, Messa C. Effects of Lactobacillus rhamnosus GG on the cell growth and polyamine metabolism in HGC-27 human gastric cancer cells. Nutr Cancer. 59: 106 - 14. 2007. 133 Choi SS, Kim Y, Han KS, You S, Oh S, Kim SH. Effects of Lactobacillus strains on cancer cell proliferation and oxidative stress in vitro. Lett Appl Microbiol. 42: 452 - 58. 2006. 134 Benkerroum N, Daoudi A, Hamraoui T, Ghalfi H, Thiry C, Duroy M, Evrart P, Roblain D, Thonart P. Lyophilised preparations of bacteriocinogenic Lactobacillus curvatus and Lactococcus lactis subsp. lactis as potential protective adjuncts to control Listeria monocytogenes in dry-fermented sausages. J Appl Microbiol. 98: 56 - 63. 2005. 135 Littell RC, Stroup WW, Freund RJ. SAS for linear models. 4th edition. SAS Publishing. 2002. 136 Paul David Allison PD. Survival Analysis Using the SAS System: A Practical Guide. 6th edition. SAS Publishing. 1995. 137 Franks F. Freeze-drying of bioproducts: putting principles into practice, Eur. J. Pharm. Biopharm. 45: 221 - 29. 1998. 138 Abdul-Fattah AM, Kalonia DS, Pikal MJ. The challenge of drying method selection for protein pharmaceuticals: product quality implications. J Pharm Sci. 96: 1886 - 916. 2007. 180 139 Repnik U, Bergant M, Wraber B, Jeras M. Late dendritic cells are still able to evoke a potent alloreactive CTL response. Immunobiology. 213: 51 - 64. 2008. 140 Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246: 1306 09. 1989. 141 Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol. 9: 541 - 73. 1993. 142 Giamila Fantuzzi G. Cytokine Knockouts. 2nd edition. Humana Press. 2003. 143 Rothenberg ME. Chemokines in Allergic Disease. Informa Health Care. 2000. 144 Summerhayes IC, Franks LM. Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J Natl Cancer I. 62: 1017 - 23. 1979. 145 Ikeda N, Honda I, Yano I, Koyama A, Toida I. Bacillus calmette-guerin Tokyo172 substrain for superficial bladder cancer: characterisation and antitumour effect. J Urol. 173: 1507 - 12. 2005. 146 Böhle A, Rüsch-Gerdes S, Ulmer AJ, Braasch H, Jocham D. The effect of lubricants on viability of bacillus Calmette-Guerin for intravesical immunotherapy against bladder carcinoma. J Urol. 155: 1892 - 96. 1996. 181 147 Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother. 61: 299 - 305. 2007. 148 Nseyo UO, Lamm DL. Immunotherapy of bladder cancer. Semin Surg Oncol. 13: 342 - 49. 1997. 149 Reid G, Beuerman D, Heinemann C, Bruce AW. Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora. FEMS Immunol Med Microbiol. 32: 37 - 41. 2001. 150 Campieri C, Campieri M, Bertuzzi V, Swennen E, Matteuzzi D, Stefoni S, Pirovano F, Centi C, Ulisse S, Famularo G, De Simone C. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int. 60: 1097 - 105. 2001. 151 Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, De La Taille A, Abbou CC, Chopin DK. T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after and courses of bacillus Calmette-Guerin for superficial bladder cancer. J Urol. 166: 2142 - 47. 2001. 152 Saint F, Kurth N, Maille P, Vordos D, Hoznek A, Soyeux P, Patard JJ, Abbou CC, Chopin DK. Urinary IL2 assay for monitoring intravesical bacillus Calmette-Guerin response of superficial bladder cancer during induction course and maintenance therapy. Int J Cancer. 107: 434 - 40. 2003. 182 153 Hudson MA, Catalona WJ, Ritchey JK, Aslanzadeh J, Brown EJ, Ratliff TL. Choice of an optimal diluent for intravesical bacillus Calmette-Guerin administration. J Urol. 142: 1438 - 41. 1989. 154 Luo Y, Chen X, O'Donnell MA. Mycobacterium bovis bacillus Calmette-Guerin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin Exp Immunol. 147: 370 - 78. 2007. 155 Reale M, Intorno R, Tenaglia R, Feliciani C, Barbacane RC, Santoni A, Conti P. Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guerin immunotherapy. Cancer Immunol Immunother. 51: 91 - 98. 2002. 156 Asensio VC, Lassmann S, Pagenstecher A, Steffensen SC, Henriksen SJ, Campbell IL. C10 is a novel chemokine expressed in experimental inflammatory demyelinating disorders that promotes recruitment of macrophages to the central nervous system. Am. J. Pathol. 154: 1181 - 91. 1999. 157 Coelho AL, Schaller MA, Benjamim CF, Orlofsky AZ, Hogaboam CM, Kunkel SL. The chemokine CCL6 promotes innate immunity via immune cell activation and recruitment. J Immunol. 179(8): 5474 - 82. 2007. 158 Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C, Rollins BJ. Abnormalities in monocyte recruitment and cytokine expression 183 in monocyte chemoattractant protein 1-deficient mice J. Exp. Med. 187: 601 08. 1998. 159 Rittner HL, Mousa SA, Labuz D, Beschmann K, Schäfer M, Stein C, Brack A. Selective local PMN recruitment by CXCL1 or CXCL2/3 injection does not cause inflammatory pain. J Leukoc Biol. 79(5): 1022 - 32. 2006. 160 Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. New Engl J Med. 354: 610 - 21. 2006. 161 Lockey RF, Bukantz SC, Bousquet J. Allergens and Allergen Immunotherapy. Allergens and Allergen Immunotherapy. 3rd Edition. Informa Health Care. 2004. 162 Whiting D, Hsieh G, Yun JJ, Banerji A, Yao W, Fishbein MC, Belperio J, Strieter RM, Bonavida B, Ardehali A. Chemokine monokine induced by IFNgamma/CXC chemokine ligand stimulates T lymphocyte proliferation and effector cytokine production. J Immunol. 172(12): 7417 - 24. 2004. 163 Robertson MJ. Role of chemokines in the biology of natural killer cells. J Leukoc Biol. 71: 173 - 83. 2002. 164 Fridman WH. Regulation of B-cell activation and antigen presentation by Fc receptors. Curr Opin Immunol. 3: 355 - 60. 1993. 165 Mosser DM. Receptors on phagocytic cells involved in microbial recognition. Immunol Ser. 60: 99 - 114. 1994. 184 166 Brandau S, Suttmann H, Riemensberger J, Seitzer U, Arnold J, Durek C, Jocham D, Flad HD, Böhle A. Perforin-mediated lysis of tumour cells by Mycobacterium bovis Bacillus Calmette-Guerin-activated killer cells. Clin Cancer Res. 6: 3729 - 38. 2000. 167 Kemp TJ, Ludwig AT, Earel JK, Moore JM, Vanoosten RL, Moses B, Leidal K, Nauseef WM, Griffith TS. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood. 106: 3474 - 82. 2005. 168 Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, O'Donnell MA, Griffith TS. Tumour necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumour activity. Cancer Res. 64: 3386 - 90. 2004. 169 de Boer EC, Westerhof AC, Kolk AH, Kuijper S, Kurth KH, Schamhart DH. Polymerase chain reaction based method for the detection of BCG retention after intravesical instillation in guinea pig bladders. Eur Urol. 37: 488 - 93. 2000. 170 Di Caro S, Tao H, Grillo A, Elia C, Gasbarrini G, Sepulveda AR, Gasbarrini A. Effects of Lactobacillus GG on genes expression pattern in small bowel mucosa. Dig Liver Dis. 37: 320 - 29. 2005. 171 Dotan I, Rachmilewitz D. Probiotics in inflammatory bowel disease: possible mechanisms of action. Curr Opin Gastroenterol. 21: 426 - 30. 2005. 185 172 Cremona S, Laye S, Dantzer R, Parnet P. Blockade of brain type II interleukin-1 receptors potentiates IL1beta-induced anorexia in mice. Neurosci Lett. 246: 101 - 4. 1998. 173 Sheih YH, Chiang BL, Wang LH, Liao CK, Gill HS. Systemic immunityenhancing effects in healthy subjects following dietary consumption of the lactic acid bacterium Lactobacillus rhamnosus HN001. J Am Coll Nutr. 20: 149 - 56. 2001. 174 Shu Q, Gill HS. Immune protection mediated by the probiotic Lactobacillus rhamnosus HN001 (DR20) against Escherichia coli O157:H7 infection in mice. FEMS Immunol Med Microbiol. 34: 59 - 64. 2002. 175 Kitazawa H, Ino T, Kawai Y, Itoh T, Saito T. A novel immunostimulating aspect of Lactobacillus gasseri: induction of "Gasserokine" as chemoattractants for macrophages. Int J Food Microbiol. 77: 29 - 38. 2002. 176 Fichera GA, Giese G. Non-immunologically-mediated cytotoxicity of Lactobacillus casei and its derivative peptidoglycan against tumour cell lines. Cancer Lett. 85: 93 - 103. 1994. 177 Engel D, Dobrindt U, Tittel A, Peters P, Maurer J, Gütgemann I, Kaissling B, Kuziel W, Jung S, Kurts C. Tumour necrosis factor alpha- and inducible nitric oxide synthase-producing dendritic cells are rapidly recruited to the bladder in 186 urinary tract infection but are dispensable for bacterial clearance. Infect Immun. 74: 6100 - 07. 2006. 178 Paul WE. Fundamental Immunology. 6th Edition. Lippincott Williams & Wilkins. 2008. 179 Drakes M, Blanchard T, Czinn S. Bacterial probiotic modulation of dendritic cells. Infect Immun. 72: 3299 - 309. 2004. 180 de Vries J, Krooshoop D, Scharenborg N, Lesterhuis J, Diepstra H, van Muijen G, Strijk S, Ruers T, Boerman O, Oyen W, Adema G, Punt C, Figdor C. Effective Migration of Antigen-pulsed Dendritic Cells to Lymph Nodes in Melanoma Patients Is Determined by Their Maturation State. Cancer Res. 63: 12 - 17. 2003. 181 Perdigon G, de Macias ME, Alvarez S, Oliver G, de Ruiz Holgado AA. Effect of perorally administered lactobacilli on macrophage activation in mice. Infect Immun. 53: 404 - 10. 1986. 182 Coffman RL. Surface antigen expression and immunoglobulin gene rearrangement during mouse pre-B cell development. Immunol Rev. 69: - 23. 1982. 183 Johnson P, Maiti A. CD45: A family of leukocyte-specific cell surface glycoproteins. In: Herzenberg LA, Weir DM, Blackwell C, ed. Weir's Handbook of Experimental Immunology, Vol 2. Cambridge: Blackwell Science. 1997. 187 184 Zlotta AR, Van Vooren JP, Denis O, Drowart A, Daffé M, Lefèvre P, Schandene L, De Cock M, De Bruyn J, Vandenbussche P, Jurion F, Palfliet K, Simon J, Schulman CC, Content J, Huygen K. What are the immunologically active components of bacille Calmette-Guérin in therapy of superficial bladder cancer? Int J Cancer. 87: 844 - 52. 2000. 185 Naito S, Koga H, Yamaguchi A, Fujimoto N, Hasui Y, Kuramoto H, Iguchi A, Kinukawa N. Kyuhu University Urological Onocology Group. Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of bladder cancer. J Urol. 179: 485 - 90. 2008. 186 Bianco FJ Jr, Gervasi DC, Tiguert R, Grignon DJ, Pontes JE, Crissman JD, Fridman R, Wood DP Jr. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. Clin Cancer Res. 4: 3011 - 16. 1998. 187 Nutt JE, Durkan GC, Mellon JK, Lunec J. Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine. BJU Int. 91: 99 - 104. 2003. 188 Ang C, Chambers AF, Tuck AB, Winquist E, Izawa JI. Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder. BJU Int. 96: 803 - 05. 2005. 188 189 Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor (Flk1) and VEGF receptor (Flt4). Proc Natl Acad Sci USA. 95: 548 - 53. 1998. 190 McAveney KM, Gomella LG, Lattime EC. Induction of TH1- and TH2associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumour MB49 and BCG immunotherapy. Cancer Immunol Immunother. 39: 401 - 06. 1994. 191 Siracusano S, Vita F, Abbate R, Ciciliato S, Borelli V, Bernabei M, Zabucchi G. The role of granulocytes following intravesical BCG prophylaxis. Eur Urol. 51: 1589 - 97. 2007. 192 Simons MP, Nauseef WM, Griffith T S. Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer. Immunol Res. 39: 79 - 93. 2007. 193 Suttmann H, Lehan N, Böhle A, Brandau S. Stimulation of neutrophil granulocytes with Mycobacterium bovis bacillus Calmette-Guérin induces changes in phenotype and gene expression and inhibits spontaneous apoptosis. Infect Immun. 71: 4647 - 56. 2003. 194 Leek RD, Harris AL. Tumour-associated macrophages in breast cancer. J Mammary Gland Biol. 7: 177 - 89. 2002. 189 195 Brigati C, Noonan DM, Albini A, Benelli R. Tumours and inflammatory infiltrates: friends or foes? Clin. Exp. Metastasis 19: 247 - 58. 2002. 196 Salminen MK, Tynkkynen S, Rautelin H, Saxelin M, Vaara M, Ruutu P, Sarna S, Valtonen V, Järvinen A. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis. 35: 1155 - 60. 2002. 197 Sullivan A, Nord CE. Probiotic lactobacilli and bacteraemia in Stockholm. Scand J Infect Dis. 38: 327 - 31. 2006. 198 Ralph P, Nakoinz I. Direct toxic effects of immunopotentiators on monocytic, myelomonocytic, and histiocytic or macrophage tumour cells in culture. Cancer Res. 37: 546 - 50. 1977. 190 [...]... to Control tumour- bearing mice Array 4.1 - Proteins found to be expressed with a 2-fold difference with respect to Control tumour- bearing mice Comparison of bladder proteins from mice after 6 weeks of therapy Immune cell populations in spleen after various LGG therapies Comparisons in Mac-3+, CD19+ and Ly6G+ cell population between cured and tumour- bearing mice PSA concentration of the five colonies... stimulated with live and lyo LGG 2 instillations/week induced more cytokine/ chemokine mRNA than 1 instillation/week H&E staining of a section of a tumour- bearing bladder Survival rates of tumour- bearing mice after various LGG treatments X-ray images of Arrays 3.1 and 4.1 Representative H& E tissue sections of tumour- bearing bladders Representative images of lyo LGG and control bladder sections stained with... mAb Photomicrographs of bladder sections stained with antimouse Mac-3 mAb (macrophage) Monitoring growth of subcutaneous tumour Kaplan Meier analysis of BGC and lyo LGG therapy on the survival of tumour- bearing mice Urinary TNFα and IL10 1 week after lyo LGG instillations Microbe instillations elevated TNFα, TGFβ and IL10 transcript expression in local lymph nodes Total number of MGH cells remaining... properties of Lactobacillus species 1.5.1.1 Women’s reproductive and bladder health Lactobacillus strains are able to colonise the vagina following vaginal suppository insertion and reduce the risk of urinary tract infection, yeast vaginitis and bacterial vaginosis The rate of urinary tract infection in 25 women was compared before and after regular lactobacillus usage Prevention of urinary tract infection... live and lyo LGG therapy was found to confer a 30% survival advantage over controls (p < 0.05) xvi Oral feeding of live LGG in addition to lyo LGG instillations, did not augment lyo LGG’s anti -tumour efficiency The mice were typically cured of bladder tumour between the 2nd and 3rd instillations Lyo LGG instillations led to massive numbers of neutrophils and some macrophages infiltrating the tumour. .. European National Societies of Immunology 16th European Congress of Immunology 6 – 9 Sep 2006, Paris, France 2 A comparison of immune cells mobilisation after intravesical instillations of Mycobacterium bovis, Bacillus Calmette Guerin (BCG) and Lactobacillus rhamnosus strain GG (LGG) in mice (PD-3832) 1st Joint Meeting of European National Societies of Immunology 16th European Congress of Immunology 6 – 9... comparison of the immunomodulatory effects of Lactobacillus rhamnosus strain GG and Mycobacterium bovis, Bacillus Calmette-Guerin following instillations in healthy mice Federation of Clinical Immunology Societies – FOCIS 2006 01 – 05 Jun 2006, San Francisco xiv 4 Immunomodulatory effects of Lactobacillus rhamnosus strain GG in Healthy Mice (P109) Combined Scientific Meeting; Singhealth, National Healthcare... model of bladder cancer (Manuscript in preparation) 3 Seow SW, Bay BH, Lee YK and Mahendran R Understanding the anti -tumour mechanisms of Lactobacillus rhamnosus GG – in vitro (Manuscript in preparation) Conference Papers Poster presentation 1 An in vivo study of the immunotherapeutic potential of Lactobacillus rhamnosus GG in healthy murine bladders (PD- 2774) 1st Joint Meeting of European National... like dendritic cells and macrophages present BCG epitopes to T-helper cells culminating in T-cell activation [25] and cytokine production Polymorphonuclear (PMN) cells are early innate immune cells and the predominant subpopulation of leukocytes in the urine after BCG instillation [26] They migrate to the tumour site site after BCG instillation and mediate the recruitment of monocytes and CD4+ T-cells... experiments on normal healthy mice Treatment schedule for the orthotopic bladder tumour model Histogram of DNA content of healthy cells Live LGG induces TNFα expression Bacteria instillations led to enlarged local lymph nodes X-ray images of cRNA array Gene expression changes induced by the microbes Effect of live and lyo LGG on splenocyte TNFα and IL12p40 mRNA expression Cytokine production by splenocytes stimulated . cured and tumour- bearing mice. 103 Table 3.16 PSA concentration of the five colonies selected for subcutaneous tumour implantation. 110 Table 3.17 Odds ratio (OR) of mice bearing bladder tumour. EFFECTS OF LACTOBACILLUS ON NORMAL AND TUMOUR BEARING MICE SEOW SHIH WEE B.Sc (HON.) NUS A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY DEPARTMENT OF SURGERY. 3.14 Monitoring growth of subcutaneous tumour. 110 Figure 3.15 Kaplan Meier analysis of BGC and lyo LGG therapy on the survival of tumour- bearing mice. 112 Figure 3.16 Urinary TNF α and IL10